Get the Stockscreener App
7.23
3.60%
-0.27
After Hours:
6.91
-0.32
-4.43%
Elicio Therapeutics Inc stock is traded at $7.23, with a volume of 30,077.
It is down -3.60% in the last 24 hours and up +50.31% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$7.50
Open:
$7.52
24h Volume:
30,077
Relative Volume:
0.78
Market Cap:
$115.68M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.2825
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
+27.74%
1M Performance:
+50.31%
6M Performance:
+42.04%
1Y Performance:
-3.73%
1-Day Range:
$6.91
$7.64
1-Week Range:
$5.80
$7.94
52-Week Range:
$3.3419
$9.99
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
7.23 | 90.54M | 0 | -33.82M | -66.04M | -25.59 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
When the Price of (ELTX) Talks, People Listen - news.stocktradersdaily.com
Elicio Therapeutics announces board election results By Investing.com - Investing.com Nigeria
Elicio Therapeutics Elects New Directors at Annual Meeting - TipRanks
Elicio Therapeutics announces board election results - Investing.com
Elicio Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Elicio's (ELTX) ELI-002 Interim Analysis Anticipated in Phase 2 Trial | ELTX Stock News - GuruFocus
Elicio Therapeutics: Q1 Earnings Snapshot - CTPost
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Learn to Evaluate (ELTX) using the Charts - news.stocktradersdaily.com
Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Long Term Trading Analysis for (ELTX) - news.stocktradersdaily.com
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires - GlobeNewswire
Key Executive Appointment: Elicio Therapeutics Names New Chief Strategy and Financial Officer - Stock Titan
Elicio Therapeutics grants inducement award to new chief strategy and financial officer - MSN
(ELTX) Investment Report - news.stocktradersdaily.com
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know - MSN
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Elicio Therapeutics Advances Cancer Immunotherapy Pipeline - TipRanks
Elicio signals delay in mid-stage cancer vaccine study; shares slump - TradingView
Elicio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Elicio Therapeutics, Inc. SEC 10-K Report - TradingView
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Elicio's Latest Financial Results Reveal Key Clinical Milestones and 28.9-Month Survival Data - Stock Titan
(ELTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
ELICIO THERAPEUTICS Earnings Preview: Recent $ELTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Elicio Therapeutics Names Preetam Shah CFO -March 24, 2025 at 08:17 am EDT - MarketScreener
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire
Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch
Elicio Therapeutics Appoints New Chief Strategy and Financial Officer - TipRanks
Elicio Therapeutics appoints new CSFO amid clinical trials - Investing.com
Strategic Move: Elicio Strengthens Leadership Team Ahead of Crucial Phase 2 Trial Results - Stock Titan
Elicio Therapeutics Appoints Preetam Shah as Chief Strategy and Financial Officer - citybiz
Elicio Therapeutics, Inc. (NASDAQ:ELTX) surges 13%; individual investors who own 49% shares profited along with insiders - simplywall.st
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
The hottest cancer vaccine companies you should know about - Labiotech.eu
With 36% ownership, Elicio Therapeutics, Inc. (NASDAQ:ELTX) insiders have a lot at stake - Yahoo Finance
Objective long/short (ELTX) Report - Stock Traders Daily
How to Take Advantage of moves in (ELTX) - Stock Traders Daily
Clal Biotech Completes Elicio Divestment and Initiates Loan Repayment - TipRanks
Knoll Capital Management, LLC Acquires Significant Stake in Elic - GuruFocus
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025 - Insider Monkey
Elicio Therapeutics secures $10 million in direct offering - MSN
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):